TW202214240A - 光化性皮膚疾病等之預防或治療劑 - Google Patents

光化性皮膚疾病等之預防或治療劑 Download PDF

Info

Publication number
TW202214240A
TW202214240A TW110121115A TW110121115A TW202214240A TW 202214240 A TW202214240 A TW 202214240A TW 110121115 A TW110121115 A TW 110121115A TW 110121115 A TW110121115 A TW 110121115A TW 202214240 A TW202214240 A TW 202214240A
Authority
TW
Taiwan
Prior art keywords
group
substituted
groups
alkyl
carboxyl
Prior art date
Application number
TW110121115A
Other languages
English (en)
Chinese (zh)
Inventor
鈴木毅
近藤真弘
河野佑子
松本淳宏
Original Assignee
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商田邊三菱製藥股份有限公司 filed Critical 日商田邊三菱製藥股份有限公司
Publication of TW202214240A publication Critical patent/TW202214240A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110121115A 2020-06-10 2021-06-10 光化性皮膚疾病等之預防或治療劑 TW202214240A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020101162 2020-06-10
JP2020-101162 2020-06-10

Publications (1)

Publication Number Publication Date
TW202214240A true TW202214240A (zh) 2022-04-16

Family

ID=78846115

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110121115A TW202214240A (zh) 2020-06-10 2021-06-10 光化性皮膚疾病等之預防或治療劑

Country Status (13)

Country Link
US (1) US20230226034A1 (fr)
EP (1) EP4166139A1 (fr)
JP (1) JPWO2021251452A1 (fr)
KR (1) KR20230016008A (fr)
CN (1) CN115768428A (fr)
AR (1) AR122595A1 (fr)
AU (1) AU2021289054B2 (fr)
BR (1) BR112022025115A2 (fr)
CA (1) CA3186882A1 (fr)
IL (1) IL298951A (fr)
MX (1) MX2022015806A (fr)
TW (1) TW202214240A (fr)
WO (1) WO2021251452A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145959A1 (fr) * 2022-01-31 2023-08-03 田辺三菱製薬株式会社 Nouvelle utilisation d'un agoniste du récepteur de la mélanocortine-1
WO2024029599A1 (fr) * 2022-08-03 2024-02-08 田辺三菱製薬株式会社 Composition pharmaceutique contenant de l'acide 1-2-[(3s,4r)-1-{[ (3r,4r)-1-cyclopentyl-3-fluoro-4-(4-méthoxyphényl)pyrrolidine-3-yl]carbonyl}-4-(méthoxyméthyl)pyrrolidin-3-yl]-5-(trifluorométhyl)phényl}pipéridin-4-carboxylique ou un sel ou co-cristal pharmaceutiquement acceptable de celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334265B2 (en) 2006-08-31 2012-12-18 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
EP2259794A1 (fr) 2008-02-22 2010-12-15 Clinuvel Pharmaceuticals Limited Procédé de traitement de la photosensibilité et de la phototoxicité
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2014081846A2 (fr) * 2012-11-21 2014-05-30 University Of Cincinnati Compositions pharmaceutiques comprenant des agonistes sélectifs du récepteur de la mélanocortine 1, et méthodes thérapeutiques d'utilisation de ces compositions
US20140271742A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
WO2015067503A1 (fr) 2013-11-07 2015-05-14 Clinuvel Ag Analogues de l'alpha-msh destinés à être utilisés dans le traitement du psoriasis
MY193597A (en) * 2014-05-29 2022-10-19 Mitsubishi Tanabe Pharma Corp Novel pyrrolidine compound and application as melanocortin receptor agonist
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物
AU2018215619A1 (en) 2017-02-01 2019-08-08 Clinuvel Pharmaceuticals Ltd Alpha-MSH analogues used in the treatment of xeroderma pigmentosum
US20220073497A1 (en) 2018-12-28 2022-03-10 Mitsubishi Tanabe Pharma Corporation Crystal of pyrrolidine compound

Also Published As

Publication number Publication date
US20230226034A1 (en) 2023-07-20
KR20230016008A (ko) 2023-01-31
IL298951A (en) 2023-02-01
CA3186882A1 (fr) 2021-12-16
BR112022025115A2 (pt) 2023-02-07
WO2021251452A1 (fr) 2021-12-16
CN115768428A (zh) 2023-03-07
AU2021289054A1 (en) 2023-02-02
JPWO2021251452A1 (fr) 2021-12-16
MX2022015806A (es) 2023-03-21
AR122595A1 (es) 2022-09-21
AU2021289054B2 (en) 2024-03-21
EP4166139A1 (fr) 2023-04-19

Similar Documents

Publication Publication Date Title
Kramer et al. Small‐Molecule Inhibitors of GSK‐3: Structural Insights and Their Application to Alzheimer′ s Disease Models
Pathania et al. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors
TW202214240A (zh) 光化性皮膚疾病等之預防或治療劑
DK2433637T3 (en) Use of quinazoline derivatives for neurodegenerative diseases
EP3901151A1 (fr) Hétéroaryle halogéné et autres inhibiteurs de kinase hétérocycliques et leurs utilisations
AU2011323899A1 (en) Methods of treatment and/or prevention of scleroderma, UV injury or sunburn, formation of scars or keloids by using haloaryl substituted Aminopurines
CA3061703A1 (fr) Nouvel inhibiteur du proteasome spiro et cyclique bis-benzylidine pour le traitement du cancer, du diabete et de troubles neurologiques
US11220491B2 (en) Photoprotective compositions containing Malassezia-derived compounds and/or chemical analogs thereof
JP2014514259A (ja) 疼痛および他の障害の処置のための化合物および方法
US11202748B2 (en) Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
US20190337927A1 (en) Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
US20190381004A1 (en) Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
AU2018385364B2 (en) C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
RU2812785C1 (ru) Профилактическое или терапевтическое средство от фотодерматоза
US20200276100A1 (en) Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
CN110711194A (zh) Pk11195的新用途
EP3741757A1 (fr) Dérivé de dihydro-indolizinone
US20220040189A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
KR20220161172A (ko) 세노모르픽스용 또는 피부 노화 방지용 조성물
Wall GRM1, a potential target for human melanoma